Aragen Life Sciences Files Rs 800 Cr IPO DRHP with SEBI

Aragen Life Sciences has filed its Draft Red Herring Prospectus (DRHP) with SEBI for an Initial Public Offering (IPO). The IPO includes a fresh issue worth Rs 800 crore and an offer for sale of up to 27,329,192 equity shares.

Proceeds from the fresh issue are earmarked for debt repayment and capital expenditure at its Hyderabad and Bengaluru facilities. These funds will also support general corporate purposes for Aragen Biologics, its subsidiary.

IPO Structure & Strategic Use

Established in 2000, Aragen operates as a fully integrated contract research, development, and manufacturing organization (CRDMO). It serves global innovator and emerging life sciences companies.

• Fresh Issue: Rs 800 crore
• Offer for Sale: Up to 27,329,192 equity shares
• Fresh Issue Use: Debt repayment, capital expenditure for new equipment, general corporate purposes

Market Position & Financial Performance

Aragen Life Sciences is the largest Indian CRDMO by breadth of solutions offered. It ranks among the top three in operating revenue among its Indian peers within a global CRDMO market valued at $171 billion in fiscal 2026.

In fiscal 2026, the company partnered with 591 customers globally. This included 16 of the top 20 Big Pharma companies as of March 31, 2026.

Key Financials for FY26

• Revenue from Operations: Rs 2,178.39 crore (CAGR of 14.64%)
• Profit for the Year: Rs 257.64 crore (up 26.86%)
• Adjusted EBITDA: Rs 593.77 crore (up 15.63%)
• Adjusted Profit for the Year: Rs 283.99 crore (up 29.91%)
• Return on Capital Employed (ROCE): 18.18%
• Return on Equity (ROE): 11.96%

The IPO’s book running lead managers include Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities, and JM Financial.